DOI QR코드

DOI QR Code

Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis

  • Zhang, Ming-Qian (Department of Emergency Medicine, Yan'an Hospital of Kunming Medical University) ;
  • Lin, Xin (Department of Emergency Medicine, Yan'an Hospital of Kunming Medical University) ;
  • Li, Yan (Department of Emergency Medicine, Yan'an Hospital of Kunming Medical University) ;
  • Lu, Shuang (Department of Emergency Medicine, Yan'an Hospital of Kunming Medical University)
  • Published : 2015.03.18

Abstract

Purpose: This analysis was conducted to evaluate the efficacy and safety of irinotecan based regimens as second-line chemotherapy in treating patients with small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of irinotecan based regimens as second-line chemotherapy for patients with small cell lung cancer were identified using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated. Results: In irinotecan based regimens as second-line chemotherapy, 4 clinical studies which including 155 patients with small cell lung cancer were considered eligible for inclusion. In all chemotherapy consisted of irinotecan with or without nedaplatin. Pooled analysis suggested that, in all patients, the pooled RR was 27.1% (42/155) in irinotecan based regimens. Nausea, vomiting, diarrhea and myelosuppression were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related death occurred with the irinotecan based treatments. Conclusion: This systemic analysis suggests that irinotecan based regimens as second-line chemotherapy are associated with mild response rate and acceptable toxicity for patients with small cell lung cancer.

Keywords

Irinotecan;second-line chemotherapy;small cell lung cancer

References

  1. Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
  2. Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 upregulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
  3. Glisson B (2003). Recurrent small cell lung cancer: update. Semin Oncol, 30, 72-8.
  4. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  5. Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
  6. Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet, 366, 1385-96. https://doi.org/10.1016/S0140-6736(05)67569-1
  7. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  8. Johnson D (1997). Small cell lung cancer in the elderly patient. Semin Oncol, 24, 484-91.
  9. Matsubara N, Maemondo M, Inoue A, et al (2013). Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respir Investig, 51, 28-34. https://doi.org/10.1016/j.resinv.2012.09.004
  10. Maalouf G, Rodier J, Faivre S, Raymond E (2007). Could we expect to improve survival in small cell lung cancer. Lung Cancer, 57, S30-4. https://doi.org/10.1016/S0169-5002(07)70425-7
  11. Masuda N, Fukuoka M, Kusunoki Y, et al (1992). CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol, 10, 1225-9.
  12. Morise M, Niho S, Umemura S, et al (2014). Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer. Jpn J Clin Oncol, 44, 846-51. https://doi.org/10.1093/jjco/hyu094
  13. Noda K, Nishiwaki Y, Kawahara M, et al (2002). Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 346, 85-91. https://doi.org/10.1056/NEJMoa003034
  14. Ohe M, Oshita F, Kenmotsu Y, et al (2012). Nedaplatin and irinotecan for patients with recurrent small cell lung cancer. J Exp Ther Oncol, 10, 65-9.
  15. Pallis A, Agelidou A, Agelaki S, et al (2009). A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer, 65, 187-91. https://doi.org/10.1016/j.lungcan.2008.11.002
  16. Rosti G, Bevilacqua G, Bidoli P, et al (2006). Small cell lung cancer. Ann Oncol, 17, ii5-10. https://doi.org/10.1093/annonc/mdj940
  17. van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011). Smallcell lung cancer. Lancet, 378, 1741-55. https://doi.org/10.1016/S0140-6736(11)60165-7
  18. von Pawel J, Ardizzoni A, Thatcher N (2003). The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed small cell lung cancer (SCLC): a review of 631 patients treated with iv topotecan in 6 studies. Lung Cancer, 41, S235.
  19. Yu S, Wang Y, Hu X et al (2013). A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage treatment in refractory or relapsed small cell lung cancer. Zhongguo Fei Ai Za Zhi, 16, 470-5.

Cited by

  1. Treatment mechanism of matrine in combination with irinotecan for colon cancer vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6407
  2. Puerarin increases the chemosensitivity of hepatocellular carcinoma cells vol.14, pp.3, 2017, https://doi.org/10.3892/ol.2017.6524